Page last updated: 2024-12-09

salicylihalamide a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

salicylihalamide A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID643725
CHEMBL ID520743
MeSH IDM0366415

Synonyms (5)

Synonym
salicylihalamide a
198481-99-1
CHEMBL520743
DTXSID10349230
(2z,4z)-n-[(e)-3-[(4s,6r,7s,9e)-6,16-dihydroxy-7-methyl-2-oxo-3-oxabicyclo[10.4.0]hexadeca-1(12),9,13,15-tetraen-4-yl]prop-1-enyl]hepta-2,4-dienamide

Research Excerpts

Overview

Salicylihalamide A was reported to be a unique and highly differential cytotoxin and a potent inhibitor of the mammalian vacuolar (H(+))-ATPase.

ExcerptReferenceRelevance
"Salicylihalamide A was reported to be a unique and highly differential cytotoxin and a potent inhibitor of the mammalian vacuolar (H(+))-ATPase."( Total synthesis and initial structure-function analysis of the potent V-ATPase inhibitors salicylihalamide A and related compounds.
De Brabander, JK; Liao, X; Wang, R; Wu, Y; Xie, XS, 2002
)
1.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID367368Inhibition of V-ATPase activity in bovine brain chromaffin granule membrane2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Design, synthesis, and biological evaluation of fluorinated analogues of salicylihalamide.
AID367371Inhibition of proton transport activity of V-ATPase in pig adrenal chromaffin granule membrane by fluorescent quenching measurement2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Design, synthesis, and biological evaluation of fluorinated analogues of salicylihalamide.
AID1251287Inhibition of V-ATPase (unknown origin)2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Synthesis and structure-activity studies of the V-ATPase inhibitor saliphenylhalamide (SaliPhe) and simplified analogs.
AID367369Inhibition of V-ATPase activity in african green monkey COS7 cells assessed as increase in luminal pH of lysosomes at 1 uM after 5 hrs by fluorescent microscopy2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Design, synthesis, and biological evaluation of fluorinated analogues of salicylihalamide.
AID367366Cytotoxicity against human NCI60 cells2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Design, synthesis, and biological evaluation of fluorinated analogues of salicylihalamide.
AID384280Cytotoxicity against human SK-MEL-5 cells2008Journal of natural products, May, Volume: 71, Issue:5
Synthesis and cytotoxicity of a salicylihalamide A analogue.
AID392128Growth inhibition of human HME50 cells at 100 nM2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide.
AID392127Growth inhibition of human HME50T cells at 100 nM2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide.
AID367370Cytotoxicity against african green monkey COS7 cells at 1 uM after 5 hrs by trypan blue exclusion test2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Design, synthesis, and biological evaluation of fluorinated analogues of salicylihalamide.
AID367367Cytotoxicity against human melanoma cells2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Design, synthesis, and biological evaluation of fluorinated analogues of salicylihalamide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's22 (84.62)29.6817
2010's4 (15.38)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.24 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (15.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]